Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients:
All studies: RR 0.66 [95%CI 0.53, 0.83],
p < 0.001; I2: 42%
RCTs: RR 0.81 [95%CI 0.54, 1.20],
p = 0.29; I2: 10%
The RCT result is non-significant, but is highly affected by the very late stage RECOVERY trial, which is not generalizable to earlier usage.
Currently there are
33 colchicine
for COVID-19 studies, showing 39%
[26‑51%] lower mortality, 43%
[-6‑69%] lower ventilation, 29%
[6‑46%] lower ICU admission, 23%
[14‑31%] lower hospitalization, and 73%
[-4‑211%] higher cases.
Zein et al., 1/12/2022, peer-reviewed, 2 authors.